Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated non-typeable haemophilus influenzae
- Development stage
- Unknown
- Lead developer
- Children's Hospital of Philadelphia
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Inactivated non-typeable Haemophilus influenzae (NTHi) is an oral bacterial vaccine candidate, specifically developed as **HI-164OV**, designed to prevent acute exacerbations in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis. The vaccine consists of killed whole-cell NTHi bacteria. Its mechanism of action is based on the concept of the common mucosal immune system; oral administration stimulates gut-associated lymphoid tissue (GALT), which primes NTHi-specific T-lymphocytes. These primed cells then migrate to the bronchial mucosa, where they enhance local immune defenses and reduce bacterial colonization and mucosal inflammation. Clinical trials have indicated that this immunotherapy can reduce the frequency and severity of exacerbations and the need for antibiotic treatment in susceptible populations, such as smokers with chronic airway disease.
- Other names
- inactivated non-typeable Haemophilus influenzaeoral NTHiNTHi vaccinekilled non-typeable Haemophilus influenzae
Beyond the preview
Go deeper on inactivated non-typeable haemophilus influenzae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated non-typeable haemophilus influenzae.